14 documents found, page 1 of 2
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive bre...
Michelon, I; Vilbert, M; Marinho, AD; Castro, CER; Dacoregio, MI; Stecca, C; Soares, LR; Batista, MV; Braga, S; Saeed, A; Cavalcante, LBackground: Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor receptor 2 (HER2)-positive BCBM population. Patients and methods: We searched PubMed, Embase, and Cochrane Library databases as well as American Soc...
Tuberculosis screening in the European migrant population: a scoping review of ...
Braga, S; Vieira, M; Duarte, R; Barbosa, P; Ramos, JPResponding to a surge in new tuberculosis (TB) cases among migrants from high-incidence countries, low-incidence European nations have heeded World Health Organization recommendations by implementing TB screening in this population. This review aims to synthesise evidence on current screening strategies for active TB and latent tuberculosis infection (LTBI) in European high-income countries, and their main barr...
Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomi...
Batista, MV; Alpuim Costa, D; Borralho, P; Braga, SThe clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available for luminal-like disease. Recently, next-generation sequencing (NGS) platforms have been used, essentially, in more advanced disease setting, in situations refractory to conve...
Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomark...
Saraiva, DP; Azeredo-Lopes, S; Antunes, A; Salvador, R; Borralho, P; Assis, B; Pereira, IL; Seabra, Z; Negreiros, I; Jacinto, A; Braga, S; Cabral, MGNeoadjuvant chemotherapy (NACT) is common in breast cancer (BC) treatment, though more than half of the patients lack an effective response. Therefore, new predictive biomarkers and alternative therapies are crucial. Previously, we proposed HLA-DR-expressing cytotoxic T lymphocytes (CTLs) as a potential biomarker of the response to NACT. To validate this observation and further investigate these cells, 202 BC p...
Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy agai...
Silva, G; Sales-Dias, J; Casal, D; Alves, S; Domenici, G; Barreto, C; Matos, C; Lemos, AR; Matias, AT; Kucheryava, K; Ferreira, A; Moita, MR; Braga, SAberrant Notch signaling is implicated in several cancers, including breast cancer. However, the mechanistic details of the specific receptors and function of ligand-mediated Notch signaling that promote breast cancer remains elusive. In our studies we show that DLL1, a Notch signaling ligand, is significantly overexpressed in ERα+ luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor pr...
Rugoscopy in human identification: a study in a sample of twins
Braga, S; Sampaio-Maia, B; Pereira, ML; Caldas, IMPalatal rugae patterns can be useful for forensic identification purposes. However, some doubts persist in concerning the pattern singularity in twins. The purpose of this study was to assess palatal rugae pattern singularity in a sample of twins. To do this, the palatal rugae patterns of 19 pairs of monozygotic twins and 47 pairs of dizygotic twins were studied. Our results showed that in monozygotic twins, no...
Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy agai...
Silva, G; Sales-Dias, J; Casal, D; Alves, S; Domenici, G; Barreto, C; Matos, C; Lemos, A; Matias, A; Kucheryava, K; Ferreira, A; Moita, MR; Braga, SThe Notch-signaling ligand DLL1 has emerged as an important player and promising therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell proliferation, survival, migration, angiogenesis and BC stem cell maintenance. In BC, DLL1 overexpression is associated with poor prognosis, particularly in estrogen receptor-positive (ER+) subtypes. Directed therapy in early and advanced BC...
Cancer During Pregnancy: How to Handle the Bioethical Dilemmas?—A Scoping Revie...
Alpuim Costa, D; Nobre, JG; de Almeida, SB; Ferreira, MH; Gonçalves, I; Braga, S; Pais, D
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to ...
Saraiva, DP; Jacinto, A; Borralho, P; Braga, S; Cabral, MGPrediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent need to promptly direct non-responder patients to alternative therapies. Infiltrating T lymphocytes, namely cytotoxic T lymphocytes (CTLs) have been appointed as predictors of response. However, cancer cells have the ability to dampen CTLs' activity and thus, the prognostic value of the CTLs, per se, is debatable. Here, we disc...
Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue
Carrascal, MA; Talina, C; Borralho, P; Gonçalo Mineiro, A; Henriques, AR; Pen, C; Martins, M; Braga, S; Sackstein, R; Videira, PABACKGROUND: The E-selectin ligands expressed by cancer cells mediate adhesion of circulating cancer cells to endothelial cells, as well as within tissue microenvironments important for tumor progression and metastasis. The identification of E-selectin ligands within cancer tissue could yield new biomarkers for patient stratification and aid in identifying novel therapeutic targets. The determinants of selectin ...